Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA has revealed that its circVec 2.1 DNA vectors show significantly enhanced and lasting in vivo protein expression over traditional mRNA methods, with the newly optimized circVec 2.2 design further boosting expression by 2-4 times. The company’s scientific leadership discussed these advancements in a webcast, underscoring the potential for improved gene therapies, including a novel ‘remove-&-replace’ gene therapy approach for Alpha-1-antitrypsin deficiency, a disease with no current effective treatments.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
